Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
68 hedge funds and large institutions have $124M invested in Syros Pharmaceuticals, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 22 reducing their positions, and 16 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
14% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 22
11% less funds holding
Funds holding: 76 → 68 (-8)
50% less capital invested
Capital invested by funds: $246M → $124M (-$122M)
50% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.83M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.81M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.2M |
| 4 |
Renaissance Technologies
New York
|
+$732K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$712K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.77M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$1.79M |
| 3 |
PP
PDT Partners
New York
|
-$618K |
| 4 |
Millennium Management
New York
|
-$582K |
| 5 |
VEA
Virtus ETF Advisers
New York
|
-$424K |
SYRS Hedge Fund Activity: Q4 2018 in Review
68 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q4 2018, worth a combined $124M — down 50% from $246M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of SYRS and 8 opened new positions — a net loss of 8 holders — while 22 trimmed existing stakes and 25 added.
The largest buyer was BlackRock, adding an estimated $2.83M. The largest seller was Vanguard Group, cutting an estimated $2.77M.
- 68 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q4 2018, down from 76 in Q3 2018.
- Funds reported $124M of Syros Pharmaceuticals, Inc. Common Stock stock for Q4 2018, down 50% quarter-over-quarter.
- 8 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q4 2018 and 16 closed out, a net change of -8 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q4 2018 was BlackRock, an estimated $2.83M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q4 2018 was Vanguard Group, an estimated $2.77M sold.
Based on aggregated 13F filings for Q4 2018.